AlphAIAlphAI — Financial news for AI agents
investing.comOCT 222 min read$ELV

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.

Original reporting
investing.com
Published Oct 22, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELV
Bullish
high confidence
Mentioned
$ELV
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ELVBullishMed
01

Why it matters

The earnings beat and higher guidance underpin the price‑target increase, suggesting a short‑term rally.

02

Market read

Analyst upgrade on earnings beat provides a fresh catalyst for ELV, likely prompting buying interest.

03

What to watch

Potential regulatory or Medicaid policy changes could affect future margins.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Elevance Health reported Q3 2026 adjusted EPS of $6.99 versus $4.70 consensus and revenue of $50.4 B, prompting analyst upgrades.

Company-level read

Ticker impact

$ELVBullishHigh confidence
Context

BofA raised Elevance Health's price target to $500 after the company beat Q3 earnings and raised its 2026 baseline.

Expected impact

likely upward pressure as investors price in the higher target and earnings beat

Evidence & confidence

Analyst upgrade with a concrete new target and fresh earnings beat provides a clear catalyst.

Market effects

Sector

Health‑care insurers may see renewed interest as Elevance's margins improve.

Regional

U.S. large‑cap health‑care sector could receive modest buying pressure.

Global

Limited to U.S. markets; no immediate global ripple.

Counterpoint

What could challenge this read

The target raise may already be priced in, limiting upside.

Key entities

  • company
    Elevance Health Inc.

    U.S. health‑insurance provider (ticker ELV).

  • analyst
    BofA Securities

    Raised price target to $500 and maintained a Buy rating.

Read at source← All news

Related articles

OCT 22
$ELVMedAI 8/10

ELV Q3 deep dive: Carelon expansion and Medicaid margin actions underpin raised outlook

ELV reported Q3 revenue of $50.44B, beating estimates, with adjusted EPS of $6.99, significantly above expectations. The company raised its full-year EPS guidance to $29. Medicaid margins stabilized due to rate increases, while CarelonRx showed strong performance. Medicare Advantage saw improved margins, and AI is being used for cost management. Management expects Medicaid margin recovery in 2027. Commercial and ACA markets show disciplined pricing and product mix shifts.

finance.yahoo.com2 min
OCT 22
$ELVMed

Elevance Health Inc (ELV) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong

Elevance Health (ELV) raised guidance for 2027, citing improved health benefits margins, Carelon solutions, and operating efficiency. Q3 2026 saw a 90.6% medical loss ratio, with Medicaid, Medicare Advantage, and ACA all outperforming. Challenges include elevated Medicaid costs, commercial group cost trends, and IDR pressures. CEO Gail Boudreaux expects at least 12% adjusted EPS growth in 2027, driven by margin improvements and efficiency gains.

finance.yahoo.com3 min
OCT 22
$ELVHighAI 8/10

Elevance Health Inc (ELV) (Q3 2026) Earnings Call Highlights: Ra

Elevance Health Inc (ELV) reported Q3 2026 adjusted EPS of $6.99, exceeding expectations. The company raised its 2026 EPS guidance to at least $29 and its earnings baseline to at least $26.75. Revenue increased to $50.4 billion, driven by higher premiums and service fees. Medical membership stood at 44.9 million, with a benefit expense ratio of 90.6%. The company expects at least 12% EPS growth in 2027, driven by margin improvements and Carelon expansion.

gurufocus.com2 min